Novo Nordisk is currently fairly valued with a gap of 6.4% relative to the price target.
The current price is $45.00, which places Novo Nordisk in the fairly valued category. The stock is considered undervalued when the price is below $43.10, and overvalued when the price exceeds $52.68.
The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Novo Nordisk, the fair value range lies between $43.10 and $52.68.
12 analysts cover Novo Nordisk. The ratings are mixed, with 41.6% Buy, 41.7% Hold and 16.6% Sell. The average price target is $47.89, which gives an upside of 6.4% from the current price.
Novo Nordisk is classified as a dividend stock and growth stock and value stock. This means the stock combines several attractive traits, including a dividend of 3.8%.
Novo Nordisk trades at a P/E ratio of 10.5, which is below the market average and can point to an attractive price. The forward P/E is 13.9. The P/S ratio is 0.6 (low — potentially undervalued relative to revenue). The P/B ratio is 6.7. The PEG ratio is 3.16 — above 2.0 suggests the stock is expensive relative to its growth rate.
Novo Nordisk has a profit margin of 37.2% (excellent) and an operating margin of 61.6%. Return on equity (ROE) is 71.4% — excellent return on equity. Return on assets (ROA) is 19.3%. The latest quarterly earnings grew 67.1% year over year — strong growth.
The Piotroski score is 6 out of 9 — good financial health. Altman Z2 is 3.37 (healthy balance sheet — low risk). The debt-to-equity ratio (D/E) is 224.6% — high debt, which raises the risk.
Short interest is 0.98% — low, the market does not expect a decline.
Novo Nordisk pays dividends to its shareholders. The most recently paid dividend was 1.28 USD per share, which corresponds to a dividend yield of 3.83%. Over the last 5 years, the annual dividend has grown by 158.5%, which shows positive dividend growth.
The payout ratio is 13.6%, which is low. This suggests the company prioritizes reinvesting in growth over dividend payments. There is good room to raise the dividend in the future.
We have registered dividend payments for Novo Nordisk since 2020-03-27. In that period the stock has paid a dividend 13 times, most recently on 2026-03-30. This stock qualifies as a stable dividend stock, because it has paid a dividend at least once a year for the last 5 years. That makes it attractive to investors looking for steady, regular dividend payments.
| Ex-date | Payment date | Amount | Currency | Period |
|---|---|---|---|---|
| 2026-03-30 | 2026-04-08 | 1.28 | USD | Unknown period |
| 2025-08-18 | 2025-08-26 | 0.58 | USD | Unknown period |
| 2025-03-31 | 2025-04-08 | 1.10 | USD | Unknown period |
| 2024-08-16 | 2024-08-26 | 0.51 | USD | Unknown period |
| 2024-03-22 | 2024-04-02 | 0.93 | USD | Unknown period |
| 2023-08-18 | 2023-08-29 | 0.44 | USD | Unknown period |
| 2023-03-24 | 2023-04-04 | 0.59 | USD | Unknown period |
| 2022-08-12 | 2022-08-23 | 0.29 | USD | Unknown period |
| 2022-03-25 | 2022-04-05 | 0.52 | USD | Unknown period |
| 2021-08-16 | 2021-08-25 | 0.28 | USD | Unknown period |
| 2021-03-26 | 2021-04-07 | 0.47 | USD | Unknown period |
| 2020-08-14 | 2020-08-25 | 0.26 | USD | Unknown period |
| 2020-03-27 | 2020-04-07 | 0.39 | USD | Unknown period |
In 2026, insiders at Novo Nordisk have made 1 transactions, all of which were purchases. On a net basis, insiders put 820,009 $ into the stock, which is a positive signal. Active insiders include Christina Law.
There has been no insider trading in the last 3 months.
Insiders have exclusively bought shares. This is a strong signal of confidence in the company's future.
Across the last 1 transactions: 1 purchases and 0 sales. A net 820,009 $ into the stock.
Latest purchase: Christina Law bought 2,350 shares at 349 $ each on 2025-08-19. The stock has since fallen 87.2%.
Who is buying: Christina Law.
The table shows the last 1 reported insider transactions in Novo Nordisk. Green rows are purchases, red rows are sales. The data is based on official filings.
| Transaction date | Name | Type | Number of shares | Price per share ($) | Total amount ($) |
|---|---|---|---|---|---|
| 2025-08-19 | Christina Law | Buy | 2,350 | 349 | 820,009 |
The following insiders have bought shares in Novo Nordisk: Christina Law. In total, 820,009 $ was bought across 1 transactions. Insider trades are legal transactions in which executives and board members buy or sell shares of their own company. These transactions are reported to the SEC and are publicly available.
Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.
Novo Nordisk A/S is in a short-term downtrend. The price of $44.53 is 9.1% below the 20-day average ($49.00). Medium term, the picture is negative: the price is 5.0% below the 50-day average ($46.87). Long term, the stock is 2.8% below the 200-day average ($45.82), which signals a long-term downtrend.
Golden Cross: The 50-day average (46.87) is above the 200-day average (45.82), which is a classic bullish signal for Novo Nordisk A/S.
Novo Nordisk A/S has an RSI of 36.0. The stock sits in the lower part of the neutral zone, which points to weak momentum without being oversold. In the current downtrend, be careful about reading this as a buying opportunity.
Daily MACD: MACD is negative (-0.241), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is below the signal line (0.539) by 0.780, which confirms growing negative momentum in the downtrend.
Weekly MACD: MACD5 is positive (0.388), which indicates a broader bullish long-term trend. MACD5 is above the signal line (-0.793) by 1.181, which confirms rising long-term momentum.
Overall MACD assessment: The daily and weekly MACD give conflicting signals. The long-term trend is bullish, but the short-term trend is bearish. Short-term momentum is still falling – a deeper pullback is possible.
Novo Nordisk A/S has an annual standard deviation of 46.5%, which classifies the stock as high risk. Sizeable price swings are normal, and the stock requires a higher risk tolerance.
Trend: Negative. The price trades below SMA50 and SMA200.
MACD trend (zero line): Daily bearish (-0.241). Weekly bullish (0.388).
MACD momentum (signal): Daily falling. Weekly rising.
RSI: 36.0 – neutral.
Technical signal: Sell
The trend is negative and MACD is below the zero line, which confirms the bearish momentum. Consider reducing the position or setting a stop-loss.